FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1996923074> ?p ?o ?g. }

• W1996923074 endingPage "25" @default.
• W1996923074 startingPage "17" @default.
• W1996923074 abstract "Nitric oxide (NO) released from NO donors can be cytotoxic in tumor cells and can enhance the transport of drugs into brain tumors by altering blood-tumor barrier permeability. The NO donor JS-K [O(2)-(2,4-dinitrophenyl) 1-[(4-ethoxycarbonyl)piperazin-1-yl]diazen-1-ium-1,2-diolate] releases NO upon enzymatic activation selectively in cells overexpressing glutathione-S-transferases (GSTs) such as gliomas. Thus, JS-K-dependent NO effects - especially on cell viability and vascular permeability - were investigated in U87 glioma cells in vitro and in an orthotopic U87 xenograft model in vivo by magnetic resonance imaging (MRI). In vitro experiments showed dose-dependent antiproliferative and cytotoxic effects in U87 cells. In addition, treatment of U87 cells with JS-K resulted in a dose-dependent activation of soluble guanylate cyclase and intracellular accumulation of cyclic guanosine monophosphate (cGMP) which was irreversibly inhibited by the selective inhibitor of soluble guanylate cyclase ODQ (1H-[1,2,4]oxadiazolo(4,3a)quinoxaline-1-one). Using dynamic contrast enhanced MRI (DCE-MRI) as a minimally invasive technique, we demonstrated for the first time a significant increase in the DCE-MRI read-out initial area under the concentration curve (iAUC60) indicating an acute increase in blood-tumor barrier permeability after i.v. treatment with JS-K. Repeated MR imaging of animals with intracranial U87 gliomas under treatment with JS-K (3.5 μmol/kg JS-K 3×/week) and of untreated controls on day 12 and 19 after tumor inoculation revealed no significant changes in tumor growth, edema formation or tumor perfusion. Immunohistochemical workup of the brains showed a significant antiproliferative effect of JS-K in the gliomas. Taken together, in vitro and in vivo data suggest that JS-K has antiproliferative effects in U87 gliomas and opens the blood-tumor barrier by activation of the NO/cGMP signaling pathway. This might be a novel approach to facilitate entry of therapeutic drugs into brain tumors. DCE-MRI is a non-invasive, repeatable imaging modality to monitor biological effects of NO donors and other experimental therapeutics in intracranial tumor models." @default.
• W1996923074 created "2016-06-24" @default.
• W1996923074 creator A5006699722 @default.
• W1996923074 creator A5032459039 @default.
• W1996923074 creator A5041166424 @default.
• W1996923074 creator A5063444565 @default.
• W1996923074 creator A5063932657 @default.
• W1996923074 creator A5066482184 @default.
• W1996923074 creator A5069348197 @default.
• W1996923074 creator A5070230951 @default.
• W1996923074 creator A5076715400 @default.
• W1996923074 creator A5080413535 @default.
• W1996923074 date "2013-04-01" @default.
• W1996923074 modified "2023-10-01" @default.
• W1996923074 title "Effects of the nitric oxide donor JS-K on the blood-tumor barrier and on orthotopic U87 rat gliomas assessed by MRI" @default.
• W1996923074 cites W128151115 @default.
• W1996923074 cites W1559249470 @default.
• W1996923074 cites W1630703597 @default.
• W1996923074 cites W182730751 @default.
• W1996923074 cites W1965728888 @default.
• W1996923074 cites W1969592847 @default.
• W1996923074 cites W1976919047 @default.
• W1996923074 cites W1977355015 @default.
• W1996923074 cites W1979183666 @default.
• W1996923074 cites W1992179114 @default.
• W1996923074 cites W1994207920 @default.
• W1996923074 cites W2014282724 @default.
• W1996923074 cites W2015839427 @default.
• W1996923074 cites W2023550986 @default.
• W1996923074 cites W2026038242 @default.
• W1996923074 cites W2031082710 @default.
• W1996923074 cites W2038145387 @default.
• W1996923074 cites W2046504033 @default.
• W1996923074 cites W2049462428 @default.
• W1996923074 cites W2053417711 @default.
• W1996923074 cites W2058800320 @default.
• W1996923074 cites W2059032684 @default.
• W1996923074 cites W2060725211 @default.
• W1996923074 cites W2061350341 @default.
• W1996923074 cites W2062628662 @default.
• W1996923074 cites W2063140724 @default.
• W1996923074 cites W2063205344 @default.
• W1996923074 cites W2063266714 @default.
• W1996923074 cites W2063422023 @default.
• W1996923074 cites W2069360283 @default.
• W1996923074 cites W2073178202 @default.
• W1996923074 cites W2074682792 @default.
• W1996923074 cites W2074898332 @default.
• W1996923074 cites W2080600302 @default.
• W1996923074 cites W2092137597 @default.
• W1996923074 cites W2092156555 @default.
• W1996923074 cites W2096287682 @default.
• W1996923074 cites W2098652851 @default.
• W1996923074 cites W2112523443 @default.
• W1996923074 cites W2112986223 @default.
• W1996923074 cites W2128590828 @default.
• W1996923074 cites W2128675236 @default.
• W1996923074 cites W2136391397 @default.
• W1996923074 cites W2142083741 @default.
• W1996923074 cites W2150984179 @default.
• W1996923074 cites W2151690732 @default.
• W1996923074 cites W2152866042 @default.
• W1996923074 cites W2165760078 @default.
• W1996923074 cites W2184834936 @default.
• W1996923074 cites W338754679 @default.
• W1996923074 cites W4293247451 @default.
• W1996923074 doi "https://doi.org/10.1016/j.niox.2013.01.003" @default.
• W1996923074 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3617040" @default.
• W1996923074 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23370169" @default.
• W1996923074 hasPublicationYear "2013" @default.
• W1996923074 type Work @default.
• W1996923074 sameAs 1996923074 @default.
• W1996923074 citedByCount "17" @default.
• W1996923074 countsByYear W19969230742014 @default.
• W1996923074 countsByYear W19969230742016 @default.
• W1996923074 countsByYear W19969230742017 @default.
• W1996923074 countsByYear W19969230742018 @default.
• W1996923074 countsByYear W19969230742019 @default.
• W1996923074 countsByYear W19969230742020 @default.
• W1996923074 countsByYear W19969230742023 @default.
• W1996923074 crossrefType "journal-article" @default.
• W1996923074 hasAuthorship W1996923074A5006699722 @default.
• W1996923074 hasAuthorship W1996923074A5032459039 @default.
• W1996923074 hasAuthorship W1996923074A5041166424 @default.
• W1996923074 hasAuthorship W1996923074A5063444565 @default.
• W1996923074 hasAuthorship W1996923074A5063932657 @default.
• W1996923074 hasAuthorship W1996923074A5066482184 @default.
• W1996923074 hasAuthorship W1996923074A5069348197 @default.
• W1996923074 hasAuthorship W1996923074A5070230951 @default.
• W1996923074 hasAuthorship W1996923074A5076715400 @default.
• W1996923074 hasAuthorship W1996923074A5080413535 @default.
• W1996923074 hasBestOaLocation W19969230742 @default.
• W1996923074 hasConcept C120882062 @default.
• W1996923074 hasConcept C134018914 @default.
• W1996923074 hasConcept C150903083 @default.
• W1996923074 hasConcept C154317977 @default.
• W1996923074 hasConcept C178790620 @default.
• W1996923074 hasConcept C181199279 @default.

• next